抄録
An attempt was made to investigate the prevention of congenital malformations in the offspring of alloxan-diabetic mice by the oral application of tolbutamide. Copulated primiparous CF#1 mice of 90 to 120 days of age were given 60mg/kg. b. wt. of alloxan intravenously on the 10th day of gestation, and then, the diabetic animals were controlled with tolubutamide of 400mg/kg. b. wt. every twelve hours from 48 hours after the alloxan injection to the 16th day of gestation by using a gastric tube (A-T group). Two other groups of mice were treated, one with only alloxan (A group) and one with only tolbutamide (T group) for comparison purposes. All mice were autopsied on the 19 th day of gestation and their fetuses were examined for external and oral malformations as well as skeletal abnormalities. In the A group, seven (14%) of 50 pregnant mice were delivered of more than one anomalous baby, and 13 (2.9%) of 454 live fetuses had malformations. In the A-T group, however, only one (1.9%) of 52 mothers produced a deformed baby (0.2% of 491 live borns). Statistical significance was found between these two groups in the number of mothers with malformed fetuses as well as deformed babies produced. In the T group, only one (0.2%) anomalous fetus was found among 498 live fetuses from 55 mothers. The oral administration of 400mg/kg. b. wt. of tolbutamide showed no teratogenic effects upon embryos of CF#1 mice. The results indicate that the prevention of the diabetic embryopathy may be possible by controlling the metabolic disorders of diabetes in the mother.
